Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management (original) (raw)

Management of Multiple Sclerosis: Clinical Review

majed naser

International Journal of Progressive Sciences and Technologies, 2023

View PDFchevron_right

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Hans-peter Hartung

Therapeutic Advances in Neurological Disorders, 2021

View PDFchevron_right

Therapeutic options in multiple sclerosis: Five new things

J. Corboy

Neurology, 2010

View PDFchevron_right

The symptomatic treatment of multiple sclerosis

Lucía Bianca

Clinical Neurology and Neurosurgery, 2002

View PDFchevron_right

Multiple sclerosis: following clues from cause to cure

Heather MacLean

The Lancet Neurology, 2009

View PDFchevron_right

Multiple Sclerosis Journal

Ayse Altintas

2013

View PDFchevron_right

Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions

Crystal Burkhardt

Missouri medicine, 2021

View PDFchevron_right

Multiple sclerosis: care needs for 2000 and beyond

Jenny Freeman

Journal of the Royal Society of Medicine, 2000

View PDFchevron_right

Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study

Ryotaro Ikeguchi

Cureus, 2023

View PDFchevron_right

Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagement

Jürgen kasper

Journal of the Neurological Sciences, 2011

View PDFchevron_right

Defining the clinical course of multiple sclerosis: Results of an international survey

Gary Cutter

Neurology, 1996

View PDFchevron_right

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

Gary Cutter

PLoS ONE, 2014

View PDFchevron_right

Primary progressive multiple sclerosis in the Polish population

Andrzej Potemkowski

Aktualności Neurologiczne, 2017

View PDFchevron_right

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

Jürgen kasper

2010

View PDFchevron_right

Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013

Gyula Lencses

Journal of the Neurological Sciences, 2016

View PDFchevron_right

A randomized clinical trial of a wellness intervention for women with multiple sclerosis

Heather Becker

Archives of Physical Medicine and Rehabilitation, 2003

View PDFchevron_right

A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies

Jamie L Weiss, PhD

Neurology and Therapy, 2022

View PDFchevron_right

Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability

Mihaela Aslan

The Journal of Rehabilitation Research and Development, 2006

View PDFchevron_right

A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis

Svetlana Egorova

Archives of Neurology, 2010

View PDFchevron_right

Identification and management of cognitive disorders in multiple sclerosis

Mike Matzke

Journal of Neurology, 2006

View PDFchevron_right

Exercise therapy for multiple sclerosis

Gert Kwakkel

Cochrane Database of Systematic Reviews, 2005

View PDFchevron_right

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Abdul Qadeer

Multiple Sclerosis and Related Disorders, 2021

View PDFchevron_right

Dealing with the Cognitive Issues Associated with Multiple Sclerosis

Helen Taggart

1993

View PDFchevron_right

Quality of Life in Multiple Sclerosis

Deborah Miller

Archives of Neurology, 1992

View PDFchevron_right

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

I. Berry

Journal of Neurology, Neurosurgery & Psychiatry, 1991

View PDFchevron_right

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

J. Corboy

Multiple Sclerosis and Related Disorders, 2014

View PDFchevron_right

Risk associated behavior in premorbid multiple sclerosis: A case-control study

David Boniface

Multiple Sclerosis and Related Disorders, 2014

View PDFchevron_right

Natural Approaches to Multiple Sclerosis

Chris Meletis

Alternative and Complementary Therapies, 2007

View PDFchevron_right

Predicting responders to therapies for multiple sclerosis

Jordi Río

Nature Reviews Neurology, 2009

View PDFchevron_right

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis

Michael J Olek

Archives of Neurology, 2006

View PDFchevron_right

Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia

Seraj Makkawi

Multiple Sclerosis and Related Disorders, 2021

View PDFchevron_right

Monthly Pulse Methylprednisolone Therapy Is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis

Serkan Ozakbas

Noro Psikiyatri Arsivi, 2017

View PDFchevron_right

Tumefactive multiple sclerosis

Cristian Camilo Campo Bedoya

Romanian Neurosurgery, 2021

View PDFchevron_right

Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study

Hans-peter Hartung

Archives of Neurology, 2009

View PDFchevron_right

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

Angray Kang

Multiple Sclerosis and Related Disorders, 2020

View PDFchevron_right